Phase 3 Trial Overview The new phase 3 trial included 445 overweight or obese adults who did not have diabetes but did have knee osteoarthritis [9]
GLP-1 drugs for heart health Trulicity (dulaglutide) was approved in 2020 for individuals with type 2 diabetes, with or without a history of heart disease, to help reduce the risk of serious cardiovascular events, like heart attacks
Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the global collaborative network
It took creative thinking to recognize that the right combination of receptor activities could harness glucagon benefits while neutralizing its drawbacks
Long-term persistence of hormonal adaptations to weight loss
Fermentable fibers that are found in food like Brussels sprouts, black beans, lentils, split peas, oats, and raspberries enhance GLP-1 release to aid in blood sugar control and optimal gut function